Vertex's kidney disease drug meets main goal in late-stage trial

Vertex Pharmaceuticals said its experimental kidney disease drug met the primary endpoint in a late-stage trial, a material positive clinical milestone. The result increases the probability of a future regulatory filing/approval pathway and is likely to move Vertex shares modestly (typical single-digit percentage reactions for late-stage readouts).

Analysis

Vertex Pharmaceuticals said its experimental kidney disease drug met the primary endpoint in a late-stage trial, a material positive clinical milestone. The result increases the probability of a future regulatory filing/approval pathway and is likely to move Vertex shares modestly (typical single-digit percentage reactions for late-stage readouts).